Cabaletta Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CABA | RNAC | ALLO | AUTL | 2126.HK | LYEL | |
|---|---|---|---|---|---|---|
| Market cap | 240.75M | 206.34M | 411.13M | 367.30M | 1.11B | 378.11M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.2 | -1.8 | -1.9 | -2.2 | -3.0 | -2.4 |
| Price/book | 1.1 | -1.6 | 0.9 | 4.9 | 2.0 | 1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −45.59% | −16.43% | +0.90% | +2.17% | −31.72% | −34.89% |
| Today | 0.00% | +6.40% | +6.25% | −2.47% | +7.91% | +43.27% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CABA news ›Cabaletta Bio (CABA) Expected to Release Earnings on Monday
Posted by Michael Walen on Nov 2nd, 2026 Cabaletta Bio (NASDAQ:CABA – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating…
Cabaletta Bio Grants 385,000 Stock Options to New Hires
PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) has granted stock options covering 385,000 shares to four newly hired employees, using equity compensation to recruit personnel as the Philadelphia biotechnology company advances…
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
Seeking Alpha - Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. - CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data exp
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- mychesco.com1
- seekingalpha.com1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.